

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 1/36, A61L 2/18, A61K 39/395	A1	(11) International Publication Number: WO 96/35710 (43) International Publication Date: 14 November 1996 (14.11.96)
(21) International Application Number: PCT/FI96/00254 (22) International Filing Date: 7 May 1996 (07.05.96) (30) Priority Data: 952196 8 May 1995 (08.05.95) FI (71) Applicant (for all designated States except US): SUOMEN PUNAINEN RISTI VERIPALVELU [FI/FI]; Kivihaantie 7, FIN-00310 Helsinki (FI). (72) Inventors; and (75) Inventors/Applicants (for US only): SUOMELA, Hannu, Veli, Herman [FI/FI]; Niittäjänkuja 4 A, FIN-01660 Vantaa (FI). HÄMÄLÄINEN, Eero, Olavi [FI/FI]; Haapalahdenkatu 8 C 22, FIN-00300 Helsinki (FI). (74) Agent: BERGGREN OY AB; P.O. Box 16, FIN-00101 Helsinki (FI).		(81) Designated States: AU, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>In English translation (filed in Finnish).</i>
(54) Title: PREPARATION OF IMMUNOGLOBULIN (57) Abstract The invention relates to a method for producing an immunoglobulin G preparation. In the method of blood fraction containing immunoglobulin is treated 60 - 72 hours with mild pepsin at a pH of about 4.4, treated by the S/D virus activation method and cleared of chemicals, pepsin and decomposition products. In addition, it can be filtered with a filter with perforations of about 35 nm at maximum. According to the invention, there are obtained extremely pure and well tolerated, virally safe products.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PREPARATION OF IMMUNOGLOBULIN

BACKGROUND OF THE INVENTION

5

The present invention relates to a method for producing immunoglobulin G. The product can be used in the treatment and prophylaxis of diseases.

10

The human organism is protected against external pathogenic organisms by an immune system, part of which consists of the immunoglobulins IgG, IgM and IgA. In order to function faultlessly as part of the immune system, the immunoglobulins must be in their native form. Thus the molecular weight of IgG must be about 150 kD, and the so-called Fc part must be unbroken and capable of functioning. IgG can lose its native form in the purification process, for instance as a result from polymerization caused by ethanol. The modified IgG fraction can activate the complement *in vivo* so strongly that the patient for whom the product is infused gets a fatal anaphylactic reaction. The capacity of the IgG fraction to bind the complement is measured *in vitro* as anticomplementary activity.

15

20 Immunoglobulin is used in the treatment of certain diseases, for instance idiopathic thrombocytopenia, as well as in protecting from infections patients who lack immunoglobulin G either as a hereditary or temporary feature (hypo- or agammaglobulinemia patients). Specific immunoglobulins, such as products containing antibodies against tetanus, rubella, anti-D or rabies, are used for protecting people against specific diseases.

25

It has been found out that hepatitis viruses have been transmitted to patients through certain immunoglobulin products. This means that all infective viruses have not been killed in the production process. Hepatitis has been diagnosed in as much as 10 - 20 % of the patients who have received intravenous immunoglobulin treatment.

30

The best known method for producing intravenous immunoglobulins is treatment with mild pepsin at pH 4 (Barandun et al, Vox Sang 7:157-174, 1962; FI patent 73,597; Suomela et al, Biotechnology of Blood Proteins, 227:261 - 265, 1993.) The aim of the pepsin treatment has been to eliminate anticomplementarity. Other possible methods are for instance intensive fractionating of immunoglobulins by proteolytic enzymes, such as pepsin or plasmin. The protein molecules in the obtained product are so highly fragmented (over half of the molecules) that anti-

35

complementary activity cannot be measured anymore (Römer et al, Develop. Biol. Standard 44:147 - 151, 1979). Protein molecules can also be treated by chemical agents, for example by sulfonating, reducing and alkylating or precipitating with polyethylene glycol or its derivatives (Römer et al., Vox Sang 42:62 - 73, 1982).

5

Hepatitis viruses can be inactivated by a solvent-detergent (S/D) treatment (US patents 4,591,505, 4,613,501, 4,481,189; Horowitz et al, Int. Assoc. Biol. Standard, 1992 Nov. 9).

- 10 In general, patients tolerate immunoglobulin treated with mild pepsin fairly well, but hepatitis transmissions from products made according to this method have been documented (Williams et al, Vox Sang 57:15 - 18, 1989).

- 15 Among the drawbacks of particularly enzymatically fractionated or chemically treated products, let us mention shortened biological half-life and inefficiency (Römer et al, Vox Sang 42:62 - 73, 1982).

DESCRIPTION OF THE INVENTION

- 20 The present invention introduces a method for producing immunoglobulin G according to claim 1 below. A few advantageous modifications of the invention are enlisted in the additional claims.

- 25 In order to eliminate anticomplementarity and inactivate viruses, the method comprises successive pepsin and S/D treatments, whereafter the chemicals, pepsin and the decomposition products of immunoglobulin used in the inactivation, are removed. Moreover, in order to eliminate viruses, there is performed filtering with a perforated filter, where the maximum perforation size is no larger than about 35 nm.

- 30 The pepsin treatment is such that it causes slight proteolysis or distinctive digestion, and advantageously of a kind used in the manufacture of products meant for clinical use. The treatment is performed at pH 3.8 - 4.6 for a suitable duration in conditions where the pepsin is enzymatically active. Most advantageously the treatment period is exceptionally long, about 60 - 72 hours, and the treatment is carried out at pH 4.2
35 - 4.5, which is higher than normal. A long treatment period has been found out to increase the virus inactivation. A long treatment period also increases the quantity of decomposition products. This is not, however, harmful in the end product, because the decomposition products are removed.

- Highly splitted products (for example ad 70 %) can also be manufactured with this method. In the solvent-detergent treatment there is used a solvent-detergent combination that decomposes the lipid envelope of viruses. There is normally used
- 5 0.3 % tri(n-butyl)phosphate and 1 % polysorbate (for example Tween 80), 1 % octoxynole (for example Triton 100) or 0.2 % sodium cholate, or 2 % tri(n-butyle)phosphate only. The treatment period is normally 4 - 6 hours, and the temperature 24 - 37 °C.
- 10 The chemicals, pepsin and split products are best removed simultaneously by binding the immunoglobulin to a cation exchanger. An agarose type of cation exchanger (for example CM-Sepharose) is most advantageously used.
- It was found out that virus filtering effectively eliminates such viruses that are not
- 15 inactivated in the S/D treatment. Filtering can be done at any stage whatever. Most advantageously it is carried out after removing the chemicals and decomposition products, or during pepsin incubation. Surprisingly it was also discovered out that pepsin treatment remarkably enhances the penetration of proteins in the filtering.
- 20 The size of the perforations in the filters used in virus removal (for example nanofilter Planova, Asahi Chemical Co., Japan) is about 35 nm at maximum, most advantageously about 15 - 20 nm.
- The suggested method combination effectively also eliminates non-enveloped
- 25 viruses and small enveloped viruses.
- Most advantageously the product is finally stabilized, for instance by adding mono- or disaccharide or sugar alcohol.
- 30 The original material can be blood plasma fractions manufactured by some known method and containing immunoglobulin G, for instance fractions purified with polyethylene glycol or chromatography. It can be normal or hyperimmune plasma, or a fraction purified from placenta. In particular, the original material can be a Cohn fraction II, which is most advantageously further purified with anion
- 35 exchanger and freeze-dried from ethanol. It is also possible to use a powder or a solution of immunoglobulin G produced by some other method, for instance a supernatant III of the Cohn fraction or a Cohn fraction II which is not further treated, with electrophoretic purity of over 90 %. The ethanol in ethanol-containing

fractions can be removed for instance by ultrafiltering, gel filtering or freeze-drying prior to the dissolution of the immunoglobulin.

5 Anion exchange treatment (for instance DEAE-Sephadex) is advantageously used as one step in the purification of the Cohn fraction.

By means of the invention, there are obtained extremely pure and well tolerated intravenously administered products that do not contain pepsin and have a lower anticomplementary activity than any of the prior art products. At least 95 %, 10 advantageously at least 98 % of the proteins in the product are IgG, and at least 90 % of the IgG is monomer or dimer. The quantity of polymeric IgG is less than 1 %, and the quantity of small fragments is less than 5 %. According to the invention, it is possible to obtain products with an IgA content below 5 mg/l, typically 2 - 3 mg/l. The prekallikrein activator content is typically less than 1 IU/ml. In addition, the 15 viral safety of the products is secured in more ways than in the prior art products.

The method can be applied to the production of both normal and specific immunoglobulins.

20 For a liquid preparation, there is extracted some solution after the cation exchange chromatography, and this solution is, for instance by means of pH adjustment, concentration, washing and filtering, manufactured to a product to be preserved as a liquid preparation.

25 The method according to the invention is realized for instance as follows: Immunoglobulin is dissolved to an aqueous solution. The pH is adjusted with a mild acid to be about 4.4. Most advantageously the acid is added to the solution in particles as fine as possible. Thus the pH is adjusted rapidly, without damaging the immunoglobulin. Pepsin is added at a weight ratio of about 1:10,000. The solution is 30 incubated about 66 hours at a temperature of roughly 35 °C. There is added a mixture of the solution and the detergent, and the incubation is continued for at least 8 hours at a temperature of 26 ± 2 °C. Immunoglobulin is bound to the cation exchanger and eluted with a biologically compatible buffer.

35 The pH of the eluate is adjusted at about 6.9. The eluate is concentrated, constant-volume washed and at the same time equilibrated to contain 3 - 15 %, advantageously 8 - 9 % saccharose, clarification filtered, portioned out and freeze-dried.

The obtained result is a dry goods product which is turned into an injection solution by adding water.

5 The injection solution manufactured according to the above description was given to 15 patients in 7 different hospitals. It was found out that the product caused less side effects than the two reference products in current use. The participants in this trial were patients who had earlier received treatment with a reference product for hypogammaglobulinemia. There was not detected any transmission of infective viruses as a result of using the product.

10

The immunoglobulin solution preserved as a liquid preparation is manufactured for instance as follows:

The original material is the solution obtained from the above described method, prior to freeze-drying, most advantageously after cation exchange. The pH of the
15 eluate obtained from the column is adjusted and the solution is concentrated by ultrafiltering. The chosen ultrafilter is advantageously of a type that is permeable to proteins with a molecular size smaller than about 150 kD. The solution is concentrated to protein content 2 - 10 % (v/w), most advantageously about 5 - 6 %. When necessary, there are added filtering agents, for instance $\text{Al}(\text{OH})_3$ gel and/or
20 diatomaceous earth, and mixed. The filtering agents are removed by filtering or centrifugation.

The solution is clarification filtered and thereafter filtered in a filter with a perforation size of 15 nm.

After filtering, 10 % (v/w) saccharose is dissolved in the solution, the pH is checked
25 and, when necessary, adjusted. Thereafter it is sterile filtered and bottled.

The solution should be kept at the temperature of 2 - 8 °C.

When manufacturing a product to be preserved as liquid preparation, it is possible to avoid the freeze-drying step, which sets limits to production and increases expenses.

30 EXAMPLE 1

A Cohn fraction II of the material is purified with a DEAE-Sephadex anion exchanger in the following conditions: the pH of gel and mild acetate buffer is 6.85 ± 0.05 , temperature 6 - 8 °C, processing period 3 hours. For a kilo of material, there is used 35 g dry anion exchanger.

35 2.66 kg purified and freeze-dried Cohn fraction II powder is dissolved to 35.64 liters of 10 % saccharose solution containing 0.2 M NaCl. It is cleared by filtering.

The pH of the solution is adjusted with 0.2 M HCl at 0 °C to 4.4, and there is added 240 mg purified porcine pepsin. The solution is cleared by filtering. The solution is

incubated for 66 hours at a temperature of 35 °C. The pH is adjusted to 5.0 with 0.2 M NaOH at 0 °C and sterile filtered.

There then is added 461 g Tween 80 and 135 g tri(n-butyl)phosphate to the solution, and it is mixed at 26 °C for one hour.

- 5 The solution is transported by a peristaltic pump to a virus-free production area, where it is further kept in a closed container for at least 6 - 20 hours. In this area, the production uses only autoclaved equipment or equipment purified of viruses in some other manner. The solution charges a 40 l CM-Sepharose-FF column, which is equilibrated with a 50 mM acetate buffer, pH 5.0. Tween 80 and the
- 10 tri(n-butyl)phosphate, pepsin and part of the immunoglobulin decomposition products flow through. The immunoglobulin attached to the column is eluted with a 15 mM sodium acetate buffer, pH 5.0, containing 0.5 M NaCl.
- The pH of the solution is adjusted to 6.9 with 0.2 M NaOH, and the solution is concentrated to about 40 liters by ultrafiltering. The protein content and salt
- 15 composition of the solution is changed by constant-volume washing with 180 liters of a solution containing 8 % (w/v) saccharose, 0.8 % glysin and 60 mM NaCl. There is performed clarification filtering, and filtering with a 15 nm filter. After sterile filtering, the solution is either freeze-dried into the final bottle and closed in a vacuum, or manufactured into a product preserved as a liquid preparation.

20

EXAMPLE 2

- A Cohn fraction III of supernatant or non-freeze-dried Cohn fraction II solution is ultrafiltered or gel filtered in order to eliminate ethanol and treated with a DEAE ion exchanger in order to remove impurities. The solution is equilibrated by constant-
- 25 volume washing to a solution with 5 - 10 % (w/v) saccharose and 0.2 % (w/v) NaCl. Production is continued according to the method described in example 1.

EXAMPLE 3

- The pH of the CM-Sepharose eluate produced according to example 1 or 2 is
- 30 adjusted to 5.1 with 0.2 M NaOH at 0 °C. The solution is concentrated in relation to protein to 5 - 10 % by ultrafiltering with a membrane filter that permeates all molecules smaller than 150 kD. There is performed constant-volume washing with 5 - 8 volumes distilled water.
- When desired, there are added, as filtering agents, Al(OH)₃ gel 10 - 30 ml/l and
- 35 diatomaceous earth filtering agent (for instance Filtercel) 5 - 40 g/l. The filtering agents are removed by centrifugation or advantageously by filtering in connection with the clarification filtering.

The solution is clarification filtered first with a preliminary filter made of glass fiber, and then with 220 nm and 100 nm membrane filters. Next it is filtered in a 15 nm filter. To the solution there is added 10 % (w/v) saccharose, after the dissolution of which the pH is checked and when necessary, the pH is adjusted to 1.5 with NaOH or HCl. The solution is sterile filtered and bottled.

REFERENCE EXAMPLE

Of a production-scale batch (4 kg immunoglobulin) there was extracted 300 ml solution from the production step prior to the pepsin digestion. The solution was divided into two parts, A and B. Part A was subjected to pepsin digestion in conditions where the pepsin ratio was 1/10,000 of the immunoglobulin weight, pH 4.4, temperature 37 °C, duration 66 hours. Part B was treated in the same manner, but without pepsin. After incubation, the pH of both solutions was adjusted to 5.0. Both parts were filtered successively with the same equipment and filter. The trans-membrane pressure was adjusted to 0.5 bar. In the filtering of part A, there was first performed a 30 min stabilizing filtration with a filtering solution. When the filtering speed was stabilized, filtering was continued for 90 minutes. The average filtering rate (mean protein flux) for solution A was $168.4 \text{ gh}^{-1}\text{m}^{-2}$. The equipment was carefully washed with solution B, and there was carried out a 30 min stabilization filtration and a 90 min filtration. The mean protein flux was $58.5 \text{ gh}^{-1}\text{m}^{-2}$. Thus the filtered protein quantity of pepsin digested immunoglobulin per time unit was threefold as compared to an undigested product.

CLAIMS

1. A method for producing an immunoglobulin G preparation from an immunoglobulin G fraction isolated from blood, **characterized** in that
 - 5 - in order to eliminate anticomplementarity and inactivate viruses, the fraction is treated with pepsin at pH 3.8 - 4.6,
 - whereafter the fraction is treated with the solvent/detergent virus inactivation method in order to inactivate viruses,
 - whereafter the chemicals, pepsin and immunoglobulin decomposition
 - 10 products used in the virus inactivation are removed, and that
 - in addition to this, at some stage and advantageously after the pepsin treatment, most advantageously also after the removal of the chemicals, pepsin and immunoglobulin decomposition products used for virus inactivation, the fraction is
 - 15 filtered through a perforated filter with perforations no larger than 35 nm, for instance no larger than about 20 nm, most advantageously no larger than about 15 nm.
2. A method according to claim 1, **characterized** in that the pepsin treatment constitutes treatment for about 60 - 72 hours with mild pepsin at the temperature of
 - 20 about 33 - 40 °C, at pH 4.2 - 4.5, most advantageously at pH roughly 4.4.
3. A method according to claim 1 or 2, **characterized** in that the chemicals, pepsin and immunoglobulin decomposition products used in virus inactivation are removed by treating with an ion exchanger, most advantageously cation exchanger.
 - 25
4. A method according to claim 3, **characterized** in that the immunoglobulin is attached to the cation exchanger and eluated from it by a buffer with a pH of about 5.
5. A method according to any of the claims 1 - 4, **characterized** in that the product also is concentrated, preferably by ultrafiltering, to a content of 2 - 10 w/w %, most advantageously to about 5 - 6 w/w %, and sterile filtered.
 - 30
6. A method according to claim 5, **characterized** in that the product is concentrated and constant-volume washed in an ultrafiltering device with a filter that is permeable to proteins smaller than about 150 kD.
 - 35

7. A method according to claim 2 and 4 or 5, **characterized** in that the filtering with a perforated filter of about 35 nm at maximum is carried out after concentration, prior to sterile filtering.
- 5 8. A method according to any of the claims 1 - 7, **characterized** in that the product also is freeze-dried to a product to be preserved dry, or that the product also is processed to a product to be preserved as a liquid preparation.
9. A method according to claim 8, **characterized** in that the product also is
10 processed to a product to be preserved as a liquid preparation and has an IgA content under 5 mg/l, for instance 2 - 3 mg/l.
10. A method according to any of the claims 1 - 9, **characterized** in that the original material is a Cohn fraction purified with an anion exchanger.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 96/00254

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07K 1/36, A61L 2/18, A61K 39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07K, A61L, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI, CLAIMS, BIOSIS, MEDLINE, CA, JAPIO, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0448075 A1 (MITSUBISHI RAYON CO., LTD.), 25 Sept 1991 (25.09.91), column 2, line 5 - line 35, column 5, line 3 - line 12 & line 37 - line 48; column 6, line 51 - line 56; claims	1,3-6,8-10
Y	---	2,7
Y	EP 0378208 A2 (THE GREEN CROSS CORPORATION), 18 July 1990 (18.07.90), see claims	1-10
A	Vox Sang., Volume 55, 1988, K.G. Reid et al, "Potential Contribution of Mild Pepsin Treatment at pH4 to the Viral Safety of Human Immunoglobulin Products" page 75 - page 80	1-10

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "B" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

8 August 1996

Date of mailing of the international search report

12 -08- 1996

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Ake Lindberg
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 96/00254

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Transfusion, Volume 31, 1991, C. Kempf et al, "Virus inactivation during production of intravenous immunoglobulin" page 423 - page 427 --	1-10
Y	EP 0131740 A2 (NEW YORK BLOOD CENTER, INC.), 23 January 1985 (23.01.85), see abstract and claims --	1-10
Y	US 3966906 A (HERMANN E. SCHULTZE ET AL), 29 June 1976 (29.06.76), see column 1, line 65 - line 68; column 2, line 1 - line 22; claims --	1-10
A	EP 0269405 A2 (CONNAUGHT LABORATORIES LIMITED), 1 June 1988 (01.06.88), see claims --	1-10
A	US 4436724 A (HARUO OHNISHI ET AL), 13 March 1984 (13.03.84) --	1-10
A	US 4874708 A (MARIE-FRANCE MAKULA ET AL), 17 October 1989 (17.10.89) -- -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/07/96

International application No.

PCT/FI 96/00254

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A1- 0448075	25/09/91	DE-D,T- 69114158 JP-A- 3271234 JP-B- 7078025 US-A- 5219999	25/04/96 03/12/91 23/08/95 15/06/93
EP-A2- 0378208	18/07/90	SE-T3- 0378208 DE-D,T- 69011136 ES-T- 2057191 JP-A- 3218322 US-A- 5151499	02/03/95 16/10/94 25/09/91 29/09/92
EP-A2- 0131740	23/01/85	SE-T3- 0131740 AU-B,B- 563925 AU-A- 3050384 CA-A,A- 1221910 JP-B- 6102627 JP-A- 60051116 US-A- 4540573 US-A- 4764369 US-A- 4820805	30/07/87 17/01/85 19/05/87 14/12/94 22/03/85 10/09/85 16/08/88 11/04/89
US-A- 3966906	29/06/76	FR-A- 1560201 SE-B- 308367	21/03/69 10/02/69
EP-A2- 0269405	01/06/88	SE-T3- 0269405 AU-B,B- 596714 AU-A- 8168187 CA-A- 1302884 CN-B- 1020253 DE-A- 3781104 JP-A- 1085929 JP-C- 1749314 JP-B- 4038730 RU-C- 2008916 US-A- 4849508 ZA-A- 8708815	10/05/90 26/05/88 09/06/92 14/04/93 17/09/92 30/03/89 08/04/93 25/06/92 15/03/94 18/07/89 24/05/88
US-A- 4436724	13/03/84	BE-A,A- 893798 CA-A,A- 1181008 DE-A,A- 3220309 FR-A,B- 2506616 GB-A,B- 2104080 JP-C- 1370574 JP-A- 57206608 JP-B- 61036811	03/11/82 15/01/85 16/12/82 03/12/82 02/03/83 25/03/87 18/12/82 20/08/86
US-A- 4874708	17/10/89	AU-B,B- 586869 AU-A- 5954286 CA-A,A- 1269629 EP-A,A- 0224532 FR-A,B- 2582515 JP-T- 62503036 WO-A,A- 8606963	27/07/89 24/12/86 29/05/90 10/06/87 05/12/86 03/12/87 04/12/86